7.25

3.54% -0.245

Tango Therapeutics Inc (TNGX)

Overview News Price History Option Chain Financials Why TNGX Down? Discussions Forecast

Tango Therapeutics Inc stock is traded at $7.25, with a volume of 1.30M. It is down -3.54% in the last 24 hours and down -15.24% over the past month. Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Previous Close:

$7.495

Open:

$7.48

24h Volume:

1.30M

Relative Volume:

0.50

Market Cap:

$806.64M

Revenue:

$24.30M

Net Income/Loss:

$-145.57M

P/E Ratio:

-5.4511

EPS:

-1.33

Net Cash Flow:

$-149.17M

1W Performance:

-20.98%

1M Performance:

-15.24%

6M Performance:

+395.21%

1Y Performance:

+21.92%

1-Day Range:

$7.125

$7.70

1-Week Range:

$6.69

$9.39

52-Week Range:

$1.03

$9.70

Tango Therapeutics Inc Stock (TNGX) Company Profile

Name

Tango Therapeutics Inc

Sector

Healthcare (1144)

Industry

Biotechnology (637)

Phone

(857) 320-4900

Address

201 BROOKLINE AVENUE, BOSTON

Employee

155

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

TNGX's Discussions on Twitter

Compare TNGX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNGX Tango Therapeutics Inc	7.25	1.00B	24.30M	-145.57M	-149.17M	-1.33
VRTX Vertex Pharmaceuticals Inc	420.57	108.04B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	475.81	60.75B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	583.26	61.26B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	825.21	50.32B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	316.55	34.14B	4.56B	-176.77M	225.30M	-1.7177

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-19-25	Initiated	Piper Sandler	Overweight
Jul-17-24	Initiated	Jefferies	Buy
Apr-04-24	Initiated	Cantor Fitzgerald	Overweight
Feb-12-24	Initiated	Piper Sandler	Overweight
Dec-08-23	Initiated	B. Riley Securities	Buy
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-20-21	Initiated	SVB Leerink	Outperform

View All

Tango Therapeutics Inc Stock (TNGX) Latest News

08:22 AM

Tango Therapeutics stock gains as Cantor Fitzgerald reiterates Overweight rating - Investing.com

08:22 AM

07:34 AM

How to build a dashboard for Tango Therapeutics Inc. stockJuly 2025 Selloffs & Low Drawdown Investment Strategies - newser.com

07:34 AM

06:11 AM

Is Tango Therapeutics Inc. stock entering bullish territoryChart Signals & High Conviction Buy Zone Picks - newser.com

06:11 AM

05:46 AM

Tango Therapeutics Inc. stock trend outlook and recovery pathWeekly Profit Analysis & Trade Opportunity Analysis Reports - newser.com

05:46 AM

04:19 AM

Ranking Tango Therapeutics Inc. among high performing stocks via toolsJuly 2025 News Drivers & Entry and Exit Point Strategies - newser.com

04:19 AM

02:49 AM

Why Tango Therapeutics Inc. stock is trending among retail tradersMarket Sentiment Summary & Technical Entry and Exit Tips - newser.com

02:49 AM

12:27 PM

Using AI based signals to follow Tango Therapeutics Inc.2025 Market Outlook & Proven Capital Preservation Tips - newser.com

12:27 PM

Oct 26, 2025

Multi asset correlation models including Tango Therapeutics Inc.2025 Investor Takeaways & Reliable Volume Spike Alerts - newser.com

Oct 26, 2025

Oct 24, 2025